Live Laurus Labs Share Price Chart
O 391.55
H 391.55
L 391.55
VOL 4658
Laurus Labs Performance
Days Range
Laurus Labs Fundamentals
ROCE (TTM) | 10.94 |
P/E Ratio (TTM) | 112.38 |
P/B Ratio | 5.25 |
Industry P/E | 36.12 |
Debt to Equity | 0.53 |
ROE | 9.13 |
EPS (TTM) | 3.49 |
Dividend Yield | 0.51 |
Book Value | 74.77 |
Face Value | 2 |
Laurus Labs Financials
Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | |
---|---|---|---|---|
Net Sales | 1,380.9 | 1,181.79 | 1,224.45 | 1,194.92 |
Expenses | 1,182.37 | 1,105.62 | 1,129.95 | 1,111.91 |
Profit before tax | 147.14 | 40.58 | 53.89 | 34.62 |
Operating Profit | 107.24 | 28.4 | 39.32 | 25.17 |
Net Profit | 107.24 | 28.4 | 39.32 | 25.17 |
EPS in Rs | 1.9 | 0.46 | 0.69 | 0.43 |
About Laurus Labs
History of Laurus Labs Limited
Incorporated in 2005, Laurus Labs Limited is involved in the manufacturing of pharmaceutical products.
In 2006, Research & Development (R&D) of the company started, and they signed their first patent application and in the next year, i.e., in 2007, the company established its first manufacturing unit. In the next year they supplied their first product to the USA followed by Europe in 2009. With in 8 years since its inception, in 2013, the company has crossed ₹10 billion in revenues and in the same year it received an approval from WHO for their Unit-I manufacturing site. In the next year, they commenced the construction of manufacturing Unit – II.
In 2016, they launched their IPO and got listed on the exchanges. By 2017, the company had incorporated subsidiaries in the USA and the UK and had 3 manufacturing units in India. In the next year, they expanded their international presence by incorporating a subsidiary in Germany.
As of March 2023, the company had 6 manufacturing units in Visakhapatnam in Andhra Pradesh and 1 in Hyderabad. Laurus Labs Limited have international offices located in Germany, SA, the USA and the UK. They serve their products all over India and in 62 countries worldwide. Laurus Labs Limited has more than 55 state-of-art R&D labs in India, over 90 APIs are manufactured and 322 patents filed.
Business Segments of Laurus Labs Limited
The primary business segments of the company are as follows:
- Generic Formulations: Under this segment, the company offers products or services, such as Anti-retroviral (ARV), Anti-diabetic, Cardiovascular, Proton Pump Inhibitors (PPIs) and Central nervous system (CNS). The company has dedicated formulation research labs, analytical research labs and laboratory-scale clinical supply facilities. They are capable of developing various types of dosage forms.
- CDMO-Synthesis: In this segment, the company provides Nutraceuticals, dietary supplements and cosmeceutical products. They also offer analytical and research services and commercial scale contract manufacturing.
- Bio: In this the company provides in-depth fermentation-based product development and manufacturing expertise, as a service to novel protein companies and bio-manufacturers.
- Generic APIs: Laurus Labs Limited provides generic Active Pharmaceutical Ingredients (APIs) in this segment, such as Anti-retroviral (ARV), Anti-diabetic, Cardiovascular, Proton Pump Inhibitors (PPIs) and Oncology.
As of March 31, 2023, some of the subsidiaries of Laurus Labs Limited are as follows:
- Laurus Specialty Chemicals Private Limited: This wholly-owned subsidiary of Laurus Labs Limited is involved in the business of Specialty Chemicals.
- Sriam Labs Private Limited: This wholly-owned subsidiary of the company is involved in the business of APIs and intermediates.
- Laurus Holdings Limited, United Kingdom: This wholly-owned subsidiary of Laurus Labs Limited offers support services in the pharmaceuticals field in the UK.
Key Personalities of Laurus Labs Limited
Dr Satyanarayana Chava, Founder and CEO
Dr Satyanarayana Chava is the Executive, Whole Time Director and the Chief Executive Officer of Laurus Labs Limited. He has been the Director of the company since January 21, 2006. Under his supervision, the company has grown immensely and established itself all over the world.
Peer Comparison
Stocks | Market Cap (cr) | Market Price (₹) | 52 Week Low-High (₹) |
---|---|---|---|
Supriya Lifescience Ltd | ₹2,735.21 |
332.95 6.55 (-1.93%) |
331.3 - 345 |
Celestial Biolabs Ltd | ₹4.56 |
1.75 0.00 (0.00) |
1.75 - 1.8 |
JFL Life Sciences Ltd | ₹43.99 |
39.35 0.65 (-1.63%) |
39 - 40.5 |
Procter & Gamble Health Ltd | ₹7,856.03 |
4706 32.80 (-0.69%) |
4698.1 - 4785 |
Veerhealth Care Ltd | ₹39.64 |
26 0.00 (0.00) |
26 - 26 |
What's Trending
Laurus Labs FAQs
What is the Share price of Laurus Labs (LAURUSLABS)?
Can I buy Laurus Labs (LAURUSLABS) shares?
How do I buy Laurus Labs (LAURUSLABS) from Angel One?
- Direct investment: You can buy Laurus Labs (LAURUSLABS) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Laurus Labs (LAURUSLABS) shares.
Is Laurus Labs a Debt free Company?
No, Laurus Labs is not a debt free company.
What is the main business of Laurus Labs?
The main business of Laurus Labs is to research, manufacture, and sell pharmaceutical and biotechnology-related products with a special emphasis on Hepatitis C, anti-retroviral, and oncology drugs. It also sells its generic APIs in 56 countries along with generic FDF.
Who are the promoters of Laurus Labs?
Some of the main promoters of Laurus Labs are M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava), Chava Naga Rani, Satyanarayana Chava, Chunduru Venkata Lakshmana Rao, Venkata Ravi Kumar Vantaram, Hymavathi Vantaram, Rama Suryadevara, and Krishnaveni Vasireddi.
What are the Subsidiaries that comes under Laurus Labs?
The main subsidiaries that come under Laurus Labs are Laurus Generics Inc., USA, Sriram Labs Pvt. Ltd., Laurus Holdings Ltd., Laurus Ingredients Pvt. Ltd., Laurus Generics Gmbh, Laurus Generics SA (Pty) Ltd., and Laurus Bio Private Ltd. (formerly known as Richcore Lifesciences Pvt. Ltd.).